Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and cats

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 6, 2003, Pages 1401-1418

  Abrams Ogg, Anthony C G ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ACCURACY; ACUTE LEUKEMIA; ANIMAL CARE; APLASTIC ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION REACTION; CAT DISEASE; CELL DESTRUCTION; CELL LOSS; CLINICAL FEATURE; CLINICAL OBSERVATION; DATA ANALYSIS; DISEASE SEVERITY; DOG DISEASE; EXPERIENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NONHUMAN; PRACTICE GUIDELINE; PREOPERATIVE CARE; PROPHYLAXIS; RECIPIENT; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0346243570     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00095-0     Document Type: Review

References (73)

1. Abrams-Ogg ACG. Platelet and granulocyte transfusions. In: Feldman BF, Zinkl JG, Jain NC, editors. Schalm's veterinary hematology. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 844-8.
2. Abrams-Ogg, ACG. Management of hemorrhage due to thrombocytopenia. In: Proceedings of the 20th Annual American College of Veterinary Internal Medicine Forum, Dallas, TX. Lakewood (CO): American College of Veterinary Internal Medicine 2002. p. 577-9.
3. Mohr R, Goor DA, Yellin A, Moshkovitz Y, Shinfeld A, Martinowitz U. Fresh blood units contain large potent platelets that improve hemostasis after open heart operations. Ann Thorac Surg 1992;53(4):650-4.
4. Mohr R, Martinowitz U, Lavee J, Amroch D, Ramot B, Goor DA. The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg 1988;96(4):530-4.
5. Abrams-Ogg AC, Kruth SA, Carter RF, Valli VE, Kamel-Reid S, Dube ID. Preparation and transfusion of canine platelet concentrates. Am J Vet Res 1993;54(4):635-42.
6. Allyson K, Abrams-Ogg AC, Johnstone 1B. Room temperature storage and cryopreservation of canine platelet concentrates. Am J Vet Res 1997;58(11):1338-47.
7. Adamik A, Klein A, Mischke R. Technical aspects of extraction of platelet concentrates from dogs with an automated cell separator [in German]. Dtsch Tierarztl Wochenschr 1997;104(12):523-6.
8. Klein A, Adamik A, Mischke R. Changes in platelet concentrates from dogs due to storage. I. Platelet count in in vitro function [in German]. Berl Munch Tierarztl Wochenschr 1999;112(6-7):243-53.
9. Cowles BE, Meyers KM, Wardrop KJ, Menard M, Sylvester D. Prolonged bleeding time of Chediak-Higashi cats corrected by platelet transfusion. Thromb Haemost 1992;67(6):708-12.
10. Feldman BF, Zinkl JG, Jain NC, editors. Schalm's veterinary hematology. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2000.
11. Jutkowitz LA, Rozanski EA, Moreau JA, Rush JE. Massive transfusion in dogs: 15 cases (1997-2001). J Am Vet Med Assoc 2002;220(11):1664-9.
12. Levine SP. Thrombocytopenia: pathophysiology and classification. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, editors. Wintrobe's clinical hematology. 10th edition. Baltimore: Williams & Wilkins; 1999. p. 1579-82.
13. Lee VS, Tarassenko L, Bellhouse BJ. Platelet transfusion therapy: platelet concentrate preparation and storage. J Lab Clin Med 1988;111(4):371-83.
14. Yamamoto JK, Pu R, Arai M, Pollock D, Irausquin R, Bova FJ, et al. Feline bone marrow transplantation: its use in FIV-infected cats. Vet Immunol Immunopathol 1998;65(2-4): 323-5.
15. Gasper PW, Rosen DK, Fulton R. Allogeneic marrow transplantation in a cat with acute myeloid leukemia. J Am Vet Med Assoc 1996;208(8):1280-4.
16. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986;80(6):1051-4.
17. McMillan R. Platelet-mediated bleeding disorders. In: Rakel RE, editor. Conn's current therapy 1998. Philadelphia: WB Saunders; 1998. p. 383-7.
18. Patten E. Controversies in transfusion medicine-prophylactic platelet transfusion revisited after 25 years: con. Transfusion 1992;32(4):381-5.
19. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338(8777):1223-6.
20. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287(4):155-9.
21. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16(1):1-20.
22. De Caterina R, Lanza M, Manca G, Strata GB, Maffei S, Salvatore L. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994;84(10):3363-70.
23. Knoll JS. Clinical automated hematology systems. In: Feldman BF, Zinkl JG, Jain NC, editors. Schalm's veterinary hematology. 5th edition. Philadelphia: Lippincott Williams & Wilkins: 2000. p. 3-11.
24. Hanseler E, Fehr J, Keller H. Estimation of the lower limits of manual and automated platelet counting. Am J Clin Pathol 1996;105(6):782-7.
25. Tasker S, Cripps PJ, Mackin AJ. Evaluation of methods of platelet counting in the cat. J Small Anim Pract 2001;42(7):326-32.
26. Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 1990;4(1):291-311.
27. Innerhofer P, Fries D, Margreiter J, Klingler A, Kuhbacher G, Wachter B, et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002;95(4):858-65.
28. Valeri CR, Cassidy G, Pivacek LE, Ragno G, Lieberthal W, Crowley JP, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001;41(8):977-83.
29. Brassard JA, Meyers KM, Person M, Dhein CR. Experimentally induced renal failure in the dog as an animal model of uremic bleeding. J Lab Clin Med 1994;124(1):48-54.
30. Breitschwerdt EB, Abrams-Ogg AC, Lappin MR, Bienzle D, Hancock SI, Cowan SM, et al. Molecular evidence supporting Ehrlichia canis-like infection in cats. J Vet Intern Med 2002;16(6):642-9.
31. Hersh EM, Bodey GP, Nies BA, Freitich EJ. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963. JAMA 1965;193(2):99-103.
32. Han T, Stutzman L, Cohen E, Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia: an autopsy study. Cancer 1966;19(12):1937-42.
33. Freireich EJ, Kliman A, Gaydos LA, Mantel N, Frei E. Response to repeated platelet transfusions from the same donor. Ann Intern Med 1963;59:277-87.
34. Freireich EJ. Effectiveness of platelet transfusions in leukemia and aplastic anemia. Transfusion 1966;6(1):50-4.
35. Schiffer CA. Prophylactic platelet transfusion. Transfusion 1992;32:295-8.
36. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 1973;13(5):283-90.
37. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995;35(6):498-502.
38. Murphy S, Litwin S, Herring LM, Koch P, Remischovsky J, Donaldson MH, et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982;12(4):347-56.
39. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutel E. Platelet prophylaxis in acute non-lymphoblastic leukaemia [letter]. Lancet 1978;1(8058):267.
40. Higby DJ, Cohen E, Hollan JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double-blind study. Transfusion 1974;14:440-6.
41. Ancliff PJ, Machin SJ. Trigger factors for prophylactic platelet transfusion. Blood Rev 1998;12(4):234-8.
42. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999;6(6):437-41.
43. Rebulla P. Trigger for platelet transfusion. Vox Sang 2000;78(Suppl 2):179-82.
44. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19(5):1519-38.
45. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia. Crit Rev Oncol Hematol 2002; 42:163-71.
46. Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol 2002;9(6):516-20.
47. Slichter SJ, O'Donnell MR, Weiden PL, Storb R, Schroeder ML. Canine platelet alloimmunization: the role of donor selection. Br J Haematol 1986;63(4):713-27.
48. Gaydos LA, Freiruch EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;299:905-9.
49. Aderka D, Praff G, Santo M, Weinberger A, Pinkhas J. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci 1986;291(3):147-51.
50. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997;15(3): 1143-9.
51. Rebulla P, Finazzi G. Marangoni F, Avvisati G, Gugliotta L. Tognoni G, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337(26):1870-5.
52. Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91(10):3601-6.
53. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, Pinilla I, Gomez Garcia V, Martinez C. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996;18(5):931-5.
54. Lawrence JB, Yomtovian RA, Hammons T, Masarik SR, Chongkolwatana V, Creger RJ, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 2001;41(1-2):67-76.
55. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, et al. The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 2002;94(12):3252-62.
56. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978;7(3):523-39.
57. Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999;93(9):3124-6.
58. Snyder EL, Esekowitz M, Aster R, Murphy S, Ferri P, Smith E, et al. Extended storage of platelets in a new plastic container. II. In vivo response to infusion of platelets stored for 5 days. Transfusion 1985;25(3):209-14.
59. Harker LA. Role of the spleen in thrombokinetics. J Lab Clin Med 1971;77(2):247-53.
60. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol 1976;34(3): 395-402.
61. Wennesland R, Brown E, Hopper J, Jr, Hodges JL, Jr, Guttentag OF, Scott KG, et al. Red cell, plasma and blood volume in healthy men measured by radiochromium (Cr51) cell tagging and hematocrit. J Clin Invest 1959;38(7):1065-77.
62. Brown E, Hopper J, Jr, Hodges JL, Jr, Bradley B, Wennesland R, Yamuchi H. Red cell, plasma and blood volume in healthy women measured by radiochromium (Cr51) cell tagging and hematocrit. J Clin Invest 1962;41(12):2182-90.
63. Dale GL, Wolf RF, Hynes LA, Friese P, Burstein SA. Quantitation of platelet life span in splenectomized dogs. Exp Hematol 1996;24(4):518-23.
64. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985;66(5):1105-9.
65. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion 1998;38(7):637-4.
66. Norol F, Bierling P, Roudot-Thoraval F, Le Coeur FF, Rieux C, Lavaux A, et al. Platelet transfusion: a dose-response study. Blood 1998;92(4):1448-53.
67. Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 1999;39(7):674-81.
68. Ackerman SJ, Klumpp TR, Guzman GI, Herman JH, Gaughan JP, Bleecker GC, et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 2000;40(12):1457-62.
69. Lotter MG, Badenhorst PN, Heyns AD, Van Reenen OR, Pieters H, Minnaar PC. Kinetics, distribution, and sites of destruction of canine blood platelets with In-111 oxine. J Nucl Med 1980;21(1):36-40.
70. Heilmann E, Friese P, Anderson S, George JN, Hanson SR, Burstein SA, et al. Biotinylated platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993;85(4):729-35.
71. Tanaka R, Murota A, Nagashima Y, Yamane Y. Changes in platelet life span in dogs with mitral valve regurgitation. J Vet Intern Med 2002;16(4):446-51.
72. Todorovic-Tirnanic M, Rolovic Z, Obradovic V, Bosnjakovic V. Determining the lifespan of platelets labelled with 111 In oxinate - first results. Med Pregl 1993;46(Suppl 1):97-9.
73. Tomasulo PA, Lenes BA. Platelet transfusion therapy. In: Minitove JE, McCarthy LJ, editors. Hemostatic disorders and the blood bank. Arlington, VA: American Association of Blood Banks; 1984. p. 63-89.